Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Next Previous
X
Search
Trial Profile

A Phase 2, Multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of AK120 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Manfidokimab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Akesobio Australia

    • Most Recent Events

    • 04 Jul 2022 Planned End Date changed from 30 Dec 2022 to 30 Jan 2024.
    • 04 Jul 2022 Planned primary completion date changed from 30 Nov 2022 to 30 Oct 2023.
    • 15 Oct 2021 According to Akeso Biopharma media release, the first patient enrollment in the first research center in the United States has been completed and the trial is progressing rapidly.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top